Why this call
A Healthcare Giant With Steady Growth
Steady revenue growth of 8.1%.
High profitability with 21.5% net margins.
P/E ratio of 29.8 suggests a full valuation.
Weather forecast
Johnson & Johnson (JNJ)
Sunny
Buy
Score 67/100 · Confidence 65%
The outlook is bright — conditions favour stepping in.
Weighed fromlive price action
Under the hood
What the engine weighed
Six factors, scored 0–100 from live market and financial data — the same read Wall Street does, minus the jargon.
0Overall score
Valuation
0
The stock appears expensive based on its earnings.
Growth
0
Revenue is growing at a solid, steady pace.
Profitability
0
The company is highly efficient at turning revenue into profit.
Momentum
0
The stock has been in a strong uptrend over the past year.
Fin. health
0
The company has a strong balance sheet with low debt.
Sentiment
0
Recent news flow has been constructive and focused on fundamentals.
The argument
Both sides of the sky
Every call has a case against it. Here's the honest version of both.
The bull case
- Strong revenue growth of 8.1% is impressive for a company of its size.
- Excellent profitability, with a net margin over 21%.
- Healthy balance sheet with a low debt-to-equity ratio of 0.58.
The bear case
- Valuation is a concern, with a Price-to-Earnings ratio near 30.
- The stock price is trading near its 52-week high, which could limit near-term upside.
- As a large, mature company, it may not offer the explosive growth of smaller competitors.
Get the full picture
That took thirty seconds.
Now imagine every stock you own.
You just understood JNJ without reading a single chart. The Tickerday app does this for your whole watchlist — the full thesis, price targets from next week to next year, bull and bear scenarios — and wakes you the moment the weather turns.
One plain answer for every stock — Buy, Hold, or Sell
The full picture in seconds — thesis, targets & scenarios
Sleep easy — we watch the market and wake you if it turns
Free to download · 7-day free Tickerday+ trial inside